Friday, July 10, 2026

pharma · Hypertension · Gastric Ulcer

Yung Shin Pharmaceutical

Yung NA is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hypertension, Gastric Ulcer, Atrial Fibrillation, Essential Hypertension, Dyslipidemia, Essential Hypertension. NovaPharmaNews

Taichung, CN HQ
1952 Founded
264 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Taichung, CN
Founded
1952
Employees
264
Programs
10
Drugs
13
Patents
0
Clinical program

Fimasartan/Atorvastatin Combination Tablet

Phase 1 · small molecule · Hypertension

Fimasartan/Atorvastatin Combination Tablet for Hypertension is a Phase 1 program (small_molecule) at Yung NA with 1 ClinicalTrials.gov record(s).

← All Yung NA projects Phase 1 small molecule completed

Internal code BR-FAVC-CT-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Yung NA
Phase
Phase 1
Modality
small_molecule
Indication
Hypertension
Status
completed
Trials
1